Condition: Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| University Cancer and Blood Center LLC | Athens, Georgia, United States | Suspended |
| Augusta University Medical Center | Augusta, Georgia, United States | Suspended |
| Saint Alphonsus Cancer Care Center-Boise | Boise, Idaho, United States | Suspended |
| Saint Luke's Cancer Institute - Boise | Boise, Idaho, United States | Recruiting |
| Saint Alphonsus Cancer Care Center-Caldwell | Caldwell, Idaho, United States | Suspended |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene, Idaho, United States | Recruiting |
| Saint Luke's Cancer Institute - Fruitland | Fruitland, Idaho, United States | Recruiting |
| Saint Luke's Cancer Institute - Meridian | Meridian, Idaho, United States | Recruiting |
| Saint Alphonsus Cancer Care Center-Nampa | Nampa, Idaho, United States | Suspended |
| Saint Luke's Cancer Institute - Nampa | Nampa, Idaho, United States | Recruiting |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls, Idaho, United States | Recruiting |
+ 125 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05112601